Literature DB >> 17380543

On the equivalence of some medical cost estimators with censored data.

Hongwei Zhao1, Heejung Bang, Hongkun Wang, Phillip E Pfeifer.   

Abstract

In clinical trials comparing different treatments and in health economics and outcomes research, medical costs are frequently analysed to evaluate the economical impacts of new treatment options and economic values of health-care utilization. Since Lin et al.'s first finding in the problem of applying the survival analysis techniques to the cost data, many new methods have been proposed. In this report, we establish analytic relationships among several widely adopted medical cost estimators that are seemingly different. Specifically, we report the equivalence among various estimators that were introduced by Lin et al., Bang and Tsiatis, and Zhao and Tian. Lin's estimators are formerly known to be asymptotically unbiased in some discrete censoring situations and biased otherwise, whereas all other estimators discussed here are consistent for the expected medical cost. Thus, we identify conditions under which these estimators become identical and, consequently, the biased estimators achieve consistency. We illustrate these relationships using an example from a clinical trial examining the effectiveness of implantable cardiac defibrillators in preventing death among people who had prior myocardial infarctions. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17380543     DOI: 10.1002/sim.2882

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  19 in total

1.  Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.

Authors:  V F Fragoulakis; A G Pallis; D K Kaitelidou; N M Maniadakis; V G Georgoulias
Journal:  Lung Cancer (Auckl)       Date:  2012-07-16

2.  Generalized Redistribute-to-the-Right Algorithm: Application to the Analysis of Censored Cost Data.

Authors:  Shuai Chen; Hongwei Zhao
Journal:  J Stat Theory Pract       Date:  2013-04-01

3.  Nonparametric inference for median costs with censored data.

Authors:  Hongwei Zhao; Chen Zuo; Shuai Chen; Heejung Bang
Journal:  Biometrics       Date:  2012-02-24       Impact factor: 2.571

4.  Estimating incremental cost-effectiveness ratios and their confidence intervals with different terminating events for survival time and costs.

Authors:  Shuai Chen; Hongwei Zhao
Journal:  Biostatistics       Date:  2013-02-19       Impact factor: 5.899

5.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

6.  Median-Based Incremental Cost-Effectiveness Ratio (ICER).

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Stat Theory Pract       Date:  2012-08-10

7.  Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Rong Wang; Amy J Davidoff; Shuangge Ma; Yinjun Zhao; Steven D Gore; Cary P Gross; Xiaomei Ma
Journal:  Cancer       Date:  2016-03-11       Impact factor: 6.860

8.  A flexible model for the mean and variance functions, with application to medical cost data.

Authors:  Jinsong Chen; Lei Liu; Daowen Zhang; Ya-Chen T Shih
Journal:  Stat Med       Date:  2013-05-13       Impact factor: 2.373

9.  Nonparametric inference for time-dependent incremental cost-effectiveness ratios.

Authors:  Laura M Yee; Kwun Chuen Gary Chan
Journal:  Stat Med       Date:  2015-07-27       Impact factor: 2.373

10.  Cost analysis with censored data.

Authors:  Yijian Huang
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.